Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066);2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes Care

Volumn 43, Issue 2, 2020, Pages 487-493

  Buse, John B ^a   Wexler, Deborah J ^b,c   Tsapas, Apostolos ^d   Rossing, Peter ^e,f   Mingrone, Geltrude ^g,h,i   Mathieu, Chantal ^j   D'Alessio, David A ^k   Davies, Melanie J ^l  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e STENO DIABETES CENTER   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ALBUMIN TO CREATININE RATIO; AMERICAN DIABETES ASSOCIATION; AMPUTATION; ANALYTICAL PARAMETERS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; DISEASE EXACERBATION; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES; FOOT ULCER; HEALTH CARE ORGANIZATION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK BENEFIT ANALYSIS; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASE; CLASSIFICATION; COMPLICATION; CONSENSUS; DIABETIC COMPLICATION; EUROPE; HISTORY; MALE; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; UNITED STATES;

CARDIOVASCULAR DISEASES; CONSENSUS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EUROPE; HISTORY, 21ST CENTURY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; RENAL INSUFFICIENCY, CHRONIC; SOCIETIES, MEDICAL; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES;

EID: 85078384213     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc20-er07     Document Type: Erratum

References (20)

1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-2701
2. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461-2498
3. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394: 121-130
4. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357
5. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019;139:2022-2031
6. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528-2536
7. Figtree GA, Rådholm K, Barrett TD, et al. Effects of canagliflozinon heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 2019;139:2591-2593
8. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 21 November 2019 [Epub ahead of print]. doi:10.1056/NEJMoa1911303
9. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 2018;138:1904-1907
10. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306
11. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019;140:739-750
12. Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841-851
13. Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab 2019;21:2576-2580
14. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-785
15. Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 19 September 2019 [Epub ahead of print]. doi:10.1001/jama.2019.13772
16. Rosenstock J, Perkovic V, Johansen OE, et al.; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular eventsin adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69-79
17. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519-1529
18. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7:356-367
19. Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6:370-381
20. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004-1016